Targeted EGFR Antisense Gene Therapy for Brain Cancer

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$589,796.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA109782-01
Agency Tracking Number:
CA109782
Solicitation Year:
2004
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2004-2
Small Business Information
ARMAGEN TECHNOLOGIES, INC.
ARMAGEN TECHNOLOGIES, INC., 914 COLORADO BLVD, SANTA MONICA, CA, 90401
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
RUBEN Boado
() -
Business Contact:
RUBEN BOADO
(310) 917-1275
RBOADO@NEUROGENETECH.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): The incidence of brain cancer in the U.S. is surprisingly high, and includes 15,000 new cases per year of the highly malignant primary brain cancer, glioblastoma multiforme (GBM), and about 150,000 cases per year of me

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government